Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22857098 | 0.84 | PIK3CD (0.37) | PIK3CDBRD4BRD2ALDH1A1LMNA | |
| SCHEMBL25157210 | 0.81 | BRD4 (0.43) | PIK3CDBRD4BRD2CYP2D6ALDH1A1 | |
| SCHEMBL2999035 | 0.80 | BRD4 (0.41) | PIK3CDBRD4BRD2ALDH1A1LMNA | |
| SCHEMBL25157105 | 0.75 | ALDH1A1 (0.41) | PIK3CDBRD4BRD2ALDH1A1 | |
| SCHEMBL24749998 | 0.74 | AR (0.39) | BRD4BRD2ALDH1A1 | |
| SCHEMBL2994796 | 0.71 | ALDH1A1 (0.37) | BRD4BRD2ALDH1A1 | |
| SCHEMBL25157379 | 0.71 | BRD4 (0.40) | PIK3CDBRD4BRD2ALDH1A1LMNA | |
| SCHEMBL6160033 | 0.70 | ALDH1A1 (0.34) | BRD4BRD2ALDH1A1 | |
| SCHEMBL6160038 | 0.70 | ALDH1A1 (0.34) | BRD4BRD2ALDH1A1 | |
| SCHEMBL25525530 | 0.70 | PIK3CD (0.35) | PIK3CDBRD4BRD2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | PIK3CD 1807/4885BRD4 899/4885BRD2 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.